80% of the studied sample continued to show a clinically significant decrease in depression and anxiety and a continuing improvement in mood, perception of self, spirituality, life, and self-relationships.

Alma College

Double-blind study  design:

 - Low-dose group
- High-dose group
- Administration at Baseline, 5 weeks after session 2, and a 6-month follow-up
- Control for physiological measures to establish a risk assesment


Double-blind study to understand the effects of psylocibin in decreasing symptoms of anxiety, depression and other mood disorders

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513 

Psilocybin produces substantial and
sustained decreases in depression and
anxiety in patients with life-threatening
cancer: A randomized double-blind trial

Low dose group was administered with 1 or 3mg for every 70kg in the first session and a high dose (22 to 30 mg every 80kg) in the second session.

Low-dose group in a double-blind study of psilocybin's effects in depressive and anxiety symptoms

The low dose group was administered a 1 to 3 mg dose for every 70kg in the first session to simulate a placebo, and administered with a high dose in the second session which accounts for 22 to 30mg for every 70kg.

Low-dose group in psilocybin double-blind study

The high dose group was administered a  high dose that accounted for 22 to 30mg for every 70kg, and administered with a low dose in the second session which accounts for  1 to 3 mg dose for every the first session to simulate a placebo.

High-dose group in psilocybin double-blind study

6  month follow-up in psilocybin double-blind study

Cardiovascular assessments (blood pressure and heart rate) were recorded 30, 60, 90, 120, 180, 240, 300, and 360 minutes subsequently of the administration of psilocybin. Which resulted in an increase in blood pressure and heart rate that did not established any health threat nor any relation to the subjective effects of the drug.

Learn Before

Related